SEPPIC has results of new research to further support the performance of SEPILIFT DPHP, a dipalmitoyl hydroxyproline “lipovector”.
The new anti-ageing, in vivo study was performed on 20 volunteers to evaluate the efficacy of the product versus a well-known benchmark lipopeptide. In comparison, the SEPILIFT DPHP produced excellent results while the lipopeptide at 3% did not show any statistical anti-ageing effect. At a 1% use level, SEPILIFT DPHP induced a statistically strong reduction of wrinkles compared to the placebo (-32%) and to the benchmark lipopeptide (-16%).
